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A B S T R A C T
Aim: To clarify whether quantitative assessment of pupillary light reﬂexes (PLR) can predict the outcome of
post-cardiac arrest (CA) patients during the ﬁrst 72 h after the return of spontaneous circulation (ROSC).
Methods: Fifty adults resuscitated after non-traumatic out-of-hospital CA (OHCA) (mean age 64.1 years old, 36
males) were enrolled in four emergency hospitals. PLR was sequentially measured at 0, 6, 12, 24, 48, and 72 h
after ROSC by an automated portable infrared pupillometry. PLR values for each time point were compared
between both survivors and non-survivors, and patients with either favourable (Cerebral Performance Category
(CPC) 1 or 2) or unfavourable neurological outcomes.
Results: Twenty-three patients survived for 90 days after CA, and 13 patients achieved favourable neurological
outcomes. The PLR values of the survivors and patients with favourable neurological outcomes were consistently
greater than those of non-survivors (P < 0.001) and those with unfavourable neurological outcomes
(P < 0.001), respectively. The change in PLR over time was not statistically diﬀerent between the outcome
groups. The 0-hour PLR best predicted both 90-day survival (AUC=0.82, cutoﬀ 3%, sensitivity 0.87, speciﬁcity
0.80) and favourable neurological outcomes (AUC=0.84, cutoﬀ 6%, sensitivity 0.92, speciﬁcity 0.74). No
patient with a 6-hour PLR less than 3% survived for 90 days after CA.
Conclusions: Quantitatively measured PLR was consistently greater in survivors and patients with favourable
neurological outcomes during the 72 h after ROSC. Quantitative assessment of PLR at as early as 0 h has a
potential role for prognostication in post-CA patients.
Introduction
The evaluation of pupillary light reﬂex (PLR) is a fundamental
element of neurological examinations. Traditionally, PLR is qualita-
tively assessed as absent, sluggish, or brisk by an examiner ﬂashing a
penlight and is, therefore, known to have poor inter-rater consistency
[1–3]. A hand-held portable pupilometer has recently become available
and has enabled the quantitative assessment of PLR at the patient’s
bedside. Both its clinical utility and reliability has been reported in
critical care settings [2–5].
Post-cardiac arrest syndrome (PCAS) is a complex pathophysiolo-
gical condition occurring after the return of spontaneous circulation
(ROSC). Hypoxic brain damage is the most critical consequence of this
syndrome and remains the main cause of mortality in CA-survivors [6].
Early, accurate prognostication is vital for identifying candidates for
favourable neurological recovery and survivors with irreversible brain
damage. Several approaches for predicting the outcome after CA have
been tested to date, but outcome prediction based on clinical
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examination remains challenging. Some investigations suggested that
bilaterally absent PLR at 72 h or more after CA indicated a poor out-
come irrespective of hypothermia treatment [7,8]. However, the cur-
rent recommendations regarding PLR as a predictor of outcome are
based on clinical studies that were conducted with traditional qualita-
tive assessment of PLR [9,10]. Since the qualitative assessment of PLR
may underestimate the presence of PLR, further studies are needed to
investigate the reproducibility of PLR for predicting outcomes in pa-
tients with PCAS using quantitative pupillometry [11]. The clinical
application of a pupillometer for the early prognostication in comatose
post-CA patients has been reported in some preliminary studies
[12–15]. However, poorly deﬁned and variable timing of PLR mea-
surements is a critical limitation when exploring its early prognostic
performance. Although the concept that PLR could recover over time is
well accepted, how PLR changes immediately after ROSC has surpris-
ingly never been studied.
In the present study, we sequentially measured PLR of post-CA pa-
tients using a pupillometer to clarify whether quantitative assessment
of PLR during the ﬁrst 72 h after ROSC can predict outcomes in post-CA
patients.
Patients and methods
Study design
This study was a multicentre single arm, uncontrolled, prospective,
observational study performed between December 2014 and January
2017. This study received approval from the IRB of each participating
institution and was registered with the University Hospital Medical
Information Network (Clinical trial identiﬁer: UMIN000015658). The
study methodology complied with the STARD 2015 guidelines for re-
porting diagnostic accuracy studies [16].
Patients
Fifty adult OHCA patients (≥ 18 years old) in whom spontaneous
circulation returned were prospectively enrolled in 4 university hospi-
tals and emergency medical centres in the Kanto region of Japan
(Supplemental Fig. 1). Exclusion criteria were: CA due to obvious
trauma, a do-not-attempt-resuscitation order, pregnancy, dependence
on others for daily support because of impaired brain function, terminal
stage of a known malignancy which makes 3-month survival unlikely,
and Extracorporeal Membrane Oxygenation use. Written informed
consent was obtained from the family.
Data collection and outcome assessments
Baseline demographic data included age, gender, witness status,
presence of bystander cardiopulmonary resuscitation, initial arrest
cardiac rhythm, location of CA, aetiology of CA, time from collapse to
ROSC, and Glasgow Coma Scale (GCS) after ROSC in the emergency
department. Result of qualitative PLR assessments, positive or negative,
using a penlight, and information on treatment with sedatives, opioids,
catecholamines, and temperature management was also collected.
The outcome variables were 90-day survival and neurological out-
come 90 days after CA. The Cerebral Performance Category (CPC) scale
was used to categorize neurological outcomes as follows: CPC 1, good
performance; CPC 2, moderate disability; CPC 3, severe disability; CPC
4, comatose or persistent vegetative status; and CPC 5, brain death or
death. A CPC of 1 and 2 were deﬁned as favourable neurological out-
comes, whereas a CPC of 3, 4, or 5 as poor neurological outcomes [17].
General management of post-CA patients
Post-CA care was optimized for each patient according to the
standardized institutional treatment protocol that was in accordance
with the latest guidelines at the time [10,18,19]. Comatose patients,
i.e., GCS≤ 8 with motor response of ≤5, were intubated and me-
chanically ventilated. Continuous intravenous infusions of midazolam,
propofol, and/or dexmedetomidine were used for sedation, and fen-
tanyl or buprenorphine for analgesia. Neuromuscular blocking agents,
rocuronium or vecuronium, was used in adjunct to treat shivering.
Norepinephrine, dopamine, and/or dobutamine were given when
needed to maintain optimum tissue perfusions at the discretion of
treating physicians. Patient temperature was managed at a target
temperature management (TTM) of 33–36 °C or with fever control for
non-cardiogenic CA, due to subarachnoid haemorrhage or sepsis.
Temperature management was not performed for patients presenting a
GCS > 8 in the emergency department.
Assessment of pupillary reﬂex using an automated quantitative pupillometry
Pupillary examinations were performed using an automated quan-
titative pupillometer (NeurOptics®NPi™-100 pupillometer, Neuroptics
Inc., Irvine, CA, USA) [12]. Pupillometers were rented for general
clinical purposes, and this study was conducted without ﬁnancial sup-
port nor free provision of a pupilometer from any enterprise. This de-
vice is a portable, handheld, infrared, monocular pupillometer, which
enables a quantitative measurement of the pupillary response. The
amplitude of the PLR is referred to as the percent change between
maximum pupil diameter before light stimuli and minimum pupil dia-
meter after light stimuli. Quantitative measurement of PLR was con-
ducted by the research physicians or nurses and was duplicated for each
eye at every examination. PLR was measured at 0, 6, 12, 24, 48, and
72 h after ROSC. Time variation from each time point of the PLR
measurement was strictly minimized. At each time point, the largest
PLR value of both eyes was adopted for the analysis as previously re-
ported [13].
Statistical analyses
Descriptive statistics were reported as a median with interquartile
range (IQR) or range for continuous variables, and absolute values with
percentages for categorical variables, respectively. The Chi-square test
or Fisher’s exact test were used for comparisons of binary variables.
A mixed eﬀects model was used to evaluate the diﬀerences of re-
peated measurements of PLR between the outcome groups. Hours (i.e.
0, 6, 12, 24, 48, and 72 h), outcome groups and the interaction between
hour and outcome group were included as ﬁxed eﬀects, and a random
intercept was included for each subject.
Receiver Operating Characteristics (ROC) curve analysis was per-
formed for the comparison of the area under the curve (AUC) values for
each time point of PLR. A multivariate regression model was used to
assess the eﬀects of the predictors (PLR value at each time point). The
optimal cutoﬀ values of the prognostic value of PLR according to
Youden’s J statistic with corresponding sensitivities, speciﬁcities, ne-
gative predictive value (NPV), and its 95% conﬁdence interval (CI)
were calculated. Then the highest NPV value for each time point was
obtained and the corresponding PLR cutoﬀ value was estimated. The
highest NPV value indicates that the smallest proportion of the negative
cases (non-survivor or unfavourable neurological outcome) is falsely
negative.
To address the impact of TTM on the results, the same mixed eﬀects
models and ROC analyses as above were conducted exclusively for
patients treated with TTM. P values< 0.05 were considered statisti-
cally signiﬁcant. All analyses were performed using SAS version 9.3
software (SAS Institute, Cary, NC, USA).
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Results
Patient characteristics
Baseline patient characteristics are shown in Table 1. Three post-CA
patients were not comatose, GCS > 8 in emergency department, and
were included in this study. Twenty-nine patients (58%) had CA pre-
sumed to be of cardiac cause. Non-cardiogenic aetiology included 8
(16%) with asphyxia, 3 (6%) with aneurysmal subarachnoid haemor-
rhage, 2 (4%) with strangulation, and 2 (4%) with pneumonia/sepsis.
The 0-hour PLR was actually measured at∼32 (12–61) min after ROSC,
because of the requisite time for obtaining informed consent before
enrollment. The study resulted in a 90-day survival rate of 46% in-
cluding 26% of patients with favourable neurological outcomes. Table 2
summarizes the usage of pharmacologic agents. Sedatives were used
more frequently for the survivors during 6–48 h compared to the non-
survivors, whereas catecholamine was frequently required for the non-
survivors at 0 h. The frequency of catecholamine use was not statisti-
cally diﬀerent between both groups after 6 h. More detailed information
is provided in Supplemental Table 1.
Quantitatively measured PLR values during the ﬁrst 72 h after ROSC
PLR value was associated with 90-day survival after accounting for
random eﬀects associated with individual subjects (P < 0.001). This
indicates that PLR values were consistently greater among survivors
compared to non-survivors at each time point during the ﬁrst 72 h. The
association between hour and PLR was marginally signiﬁcant
(P= 0.04), but the interaction of hour by survival status was not sig-
niﬁcant (P= 0.89), indicating that the change in PLR over time was not
signiﬁcantly diﬀerent for survivors than non-survivors (Fig. 1A). Like-
wise, PLR value was associated with 90-day favourable neurological
outcome (P < 0.001). Neither the association between hour and PLR
(P= 0.30) or the interaction of hour by neurological outcome status
(P= 0.50) were signiﬁcant. Thus, patients who achieved a 90-day fa-
vourable neurological outcome had consistently greater PLR values
compared to patients with unfavourable neurological outcomes, but the
change in PLR over time was not signiﬁcantly diﬀerent between out-
come groups (Fig. 1B).
To address the impact of the TTM on the PLR results, we further
conducted the same analyses exclusively for patients for whom TTM
was implemented. PLR values were consistently greater for 90-day
survivors compared to non-survivors (Fig. 1C) and patients who
achieved a 90-day favourable neurological outcome compared to pa-
tients with unfavourable neurological outcomes (Fig. 1D), but the
change in PLR over time was not signiﬁcantly diﬀerent between re-
spective outcome groups.
ROC analysis for prediction of 90-day survival and neurological outcome
The 0-hour PLR value best predicted 90-day survival with an AUC
value of 0.82 and a cutoﬀ value of 3% (Fig. 2A, Table 3). The PLR cutoﬀ
values with corresponding sensitivities, speciﬁcities, NPV and its 95%
CIs at each time point are shown in Table 3. The max NPV is 1.0 at 6 h,
with a PLR cutoﬀ of 3%, indicating that a PLR value less than 3% at 6 h
after ROSC predicts a 100% 90-day mortality with a 0% false negative
rate (Table 3) according to our data. As observed in the overall post-CA
patients, the 0-h PLR value was the best predictor for 90-day survival in
the TTM subgroup with an AUC of 0.81 and a PLR cutoﬀ value of 6%
(Fig. 2B, Table 3).
The 0-hour PLR value best predicted not only the survival but also a
favourable neurological outcome, with an AUC value of 0.84 and a PLR
cutoﬀ value of 6% (Fig. 3A, Table 3). The max NPV reached 1.0 at all
time points from 0 through 72 h with the PLR cutoﬀ values ranging
from 3% at 0 h to 10% at 72 h irrespective of TTM implementation
(Table 3). The 0-hour PLR was the strongest predictor of 90-day fa-
vourable neurological outcome when assessed exclusively in the TTM
subgroup, with an AUC of 0.80 and a PLR cutoﬀ value of 6% (Fig. 3B,
Table 3). Quantitative PLR showed better prognostic accuracy over 72 h
than qualitative assessment (Supplemental Table 2 and 3).
Table 1
Mean Patient characteristics.
Age; median y/o (IQR) 63 (53–79)
Male sex; n (%) 36 (72)
Witness status; n (%)
Witnessed
Not witnessed
Data missing
36
13
1
(72)
(26)
(2)
Bystander CPR; n (%)
Performed
Not performed
Data missing
24
25
1
(48)
(50)
(2)
Location of CA; n (%)
Public location
Home
Data missing
27
22
1
(54)
(44)
(2)
Initial rhythm documented by EMS; n (%)
VF/VT
PEA
Asystole
Other
14
11
20
5
(28)
(22)
(40)
(10)
Etiology of CA
Presumed cardiac cause
Non-cardiac cause
Data missing
29
20
1
(58)
(40)
(2)
Cardiac arrest time; median min (IQR) 33 (15–50)
Prehospital ROSC; n (%) 19 (38)
GCS after ROSC in ED; median (range) 3 (3–15)
Implementation of TTM 33 to 36 °C; n (%) 34 (68)
90-day survival; n (%) 23 (46)
90-day favorable neurological outcome; n (%) 13 (26)
CA, cardiac arrest; CPC, cerebral performance category; CPR, cardiopulmonary
resuscitation; ED, emergency department; EMS, emergency medical service;
GCS, Glasgow Coma Scale; IQR, interquartile range; PEA, pulseless electrical
activity; TTM, target temperature management; VF, ventricular ﬁbrillation; VT,
ventricular tachycardia.
Table 2
Usage of pharmacologic agents among 90-day survivor and non-survivor.
Type of pharmacologic
agent
Time after
ROSC
Survivors Non-
survivors
P value
Sedatives; n (%) 0 h
6 h
12 h
24 h
48 h
72 h
2 (9)
19 (83)
21 (91)
21 (91)
18 (78)
17 (74)
6 (22)
12 (46)
12 (57)
11 (58)
19 (56)
12 (86)
0.19
0.008
0.009
0.01
0.14
0.40
Analgesia; n (%) 0 h
6 h
12 h
24 h
48 h
72 h
1 (4)
14 (61)
14 (61)
13 (57)
13 (57)
11 (48)
3 (11)
9 (35)
10 (48)
8 (42)
8 (50)
6 (43)
0.38
0.05
0.38
0.35
0.69
0.77
Catecholamine; n (%) 0 h
6 h
12 h
24 h
48 h
72 h
4 (17)
12 (52)
13 (57)
11 (48)
12 (52)
9 (39)
21 (78)
18 (69)
15 (71)
12 (63)
12 (75)
9 (64)
<0.001
0.22
0.30
0.32
0.15
0.14
Percentage of non-survivors is expressed by the proportion of alive patients
receiving pharmacologic agent at each time point who were 90-day non-sur-
vivors. ROSC, return of spontaneous circulation. p < 0.05 is statistically sig-
niﬁcant.
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Discussion
To the best of our knowledge, this is the ﬁrst study that has se-
quentially measured quantitative PLR at 0 through 72 h after ROSC in
adult post-CA patients and compared PLR values with outcomes.
Surprisingly, the PLR values measured at 0 h were the best predictor for
both survival (cutoﬀ PLR value of 3%) and favourable outcome (cutoﬀ
PLR value of 6%) in post-CA patients of all measurement time points,
irrespective of TTM. Since the clinical research required informed
consent prior to enrollment and data acquisition, it took about half an
hour to measure PLR in the emergency department after ROSC.
However, a 30-min delay in the PLR measurement is reasonable in post-
CA care immediately after ROSC.
Prognostication with quantitative measurements of PLR have been
previously reported, both during CA [12] and post-CA [13–15]. The
PLR cutoﬀ value of 15% for predicting 90-day neurological outcome at
48 h after ROSC in patients who underwent TTM is in line with previous
studies [13–15]. PLR was measured on day 1 and day 2 (average of 4
and 24 h, or 16 and 46 h after CA) [13,14], or average of 24 and 48 h
after CA [15] in previous studies. In addition to the considerable time
variation of the PLR measurements, the prognostic performance of PLR
has only previously been evaluated at two time points and the optimal
timing for prognostication including immediately after ROSC remains
unexplored. Conversely, the current study has shown with a precise
timeline of serial PLR measurements, that the PLR was distinctly greater
from immediately after ROSC to 72 h for those patients who achieved
favourable outcomes, with 0-hour PLR being the best predictor of both
90-day survival and favourable neurological outcomes.
Obtaining information from the brainstem could be important for
early prognostication of CA outcome because it reﬂects the minimum
Fig. 1. Serial measurement of PLR after return
of spontaneous circulation to 72 h.
(A) PLR of survivors and non-survivors. (B)
PLR of favourable and unfavourable neurolo-
gical outcomes. (C) PLR of survivors and non-
survivors treated with TTM. (D) PLR of fa-
vourable and unfavourable neurological out-
comes treated with TTM. PLR, pupillary light
reﬂex.
Fig. 2. ROC analysis for the prediction of 90-day survival.
(A) The prediction of 90-day survival with PLR in all patients. (B) The prediction of 90-day survival with PLR only in patients treated with TTM. AUC, area under the
curve; ROC, receiver operating characteristic.
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perfusion of vital brain tissues. As patients often experience full reversal
of loss of cerebral function after general anaesthesia, monitoring cere-
bral function in post-CA patients may not be useful for early prog-
nostication [12,15,20]. Moreover, during the period of neurological
recovery following ROSC in post-CA patients with favourable outcomes,
brainstem reﬂexes return earlier than both cortical function and con-
sciousness [21]. Against the hypothesis that a better PLR restoration is
associated with favourable neurological outcomes [15], our results re-
vealed that a change in PLR over time during the ﬁrst 72 h was not
statistically diﬀerent between the outcome groups. Given the distinctly
diﬀerent PLR values between outcome groups, with its consistency
throughout the 72 h, prognostication with quantitative PLR is feasible
as early as within an hour after ROSC.
The PLR cutoﬀ value of 3% measured at 0 h after ROSC indicated
100% NPV for favourable neurological outcomes. As neuro-protective
therapies for PCAS are time sensitive, prognostication of poor outcomes
as early as possible after ROSC is critical in determining the indication
of neuro-critical care and enabling the eﬀective allocation of resources
to potential candidates with favourable neurological recovery.
Furthermore, our results revealed that a PLR of 0%, i.e. bilateral ab-
sence of PLR even with quantitative measurements, meant a 100% NPV
for predicting favourable outcomes during all time points up to 72 h
after ROSC. Since our sample size was small, further research is war-
ranted to better determine probable neurological outcome in post-CA
patients and subsequent consideration for the termination of intensive
therapies.
Table 3
Prediction of 90-day survival and favorable neurological outcome with ROC analysis.
Time after ROSC (h) PLR cutoﬀ value (%) Sensitivity Speciﬁcity NPV
(95% CI)
Max NPV PLR cutoﬀ value (%) for Max NPV
90-day survival (ALL)
0 3 0.87 0.80 0.87 (0.66–0.97) 0.87 3
6 12 0.77 0.90 0.78 (0.56–0.93) 1.00 3
12 6 0.91 0.65 0.85 (0.55–0.98) 0.91 4
24 5 0.91 0.65 0.85 (0.55–0.98) 0.91 3
48 12 0.82 0.75 0.69 (0.39–0.91) 0.80 4
72 8 0.90 0.75 0.82 (0.48–0.98) 0.89 5
90-day survival (TTM)
0 6 0.80 0.77 0.71 (0.42–0.92) 0.80 3
6 12 0.75 0.82 0.64 (0.35–0.87) 1.00 3
12 6 0.90 0.58 0.78 (0.40–0.97) 0.86 4
24 5 0.90 0.50 0.75 (0.35–0.97) 0.83 3
48 12 0.80 0.70 0.64 (0.31–0.89) 0.75 4
72 8 0.90 0.67 0.75 (0.35–0.97) 0.83 5
90-day favorable neurological outcome (ALL)
0 6 0.92 0.74 0.96 (0.81–1.00) 1.00 3
6 16 0.77 0.76 0.88 (0.69–0.98) 1.00 5
12 4 1.00 0.42 1.00 (0.72–1.00) 1.00 4
24 6 1.00 0.54 1.00 (0.77–1.00) 1.00 6
48 15 0.85 0.62 0.87 (0.60–0.98) 1.00 4
72 10 1.00 0.60 1.00 (0.74–1.00) 1.00 10
90-day favorable neurological outcome (TTM)
0 11 0.75 0.81 0.85 (0.62–0.97) 1.00 3
6 16 0.75 0.68 0.81 (0.54–0.96) 1.00 5
12 9 0.91 0.45 0.90 (0.56–1.00) 1.00 4
24 6 1.00 0.45 1.00 (0.66–1.00) 1.00 6
48 15 0.83 0.61 0.85 (0.55–0.98) 1.00 4
72 10 1.00 0.56 1.00 (0.66–1.00) 1.00 10
ALL denotes all patients, whereas TTM denotes only patients treated with target temperature management.
Fig. 3. ROC analysis for the prediction of 90-day favourable neurological outcomes.
The prediction of 90-day favourable neurological outcomes by PLR in all patients.
The prediction of 90-day favourable neurological outcomes by PLR only in patients treated with TTM.
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Outcome prediction with qualitative PLR has been strongly re-
commended to be performed 72 h or more after CA because of its low
predictive value immediately after achieving ROSC [10]. Our results
showed cutoﬀ PLR values of between 0–10% prior to 72 h post CA,
which are hardly detectable with qualitative assessment by an ex-
aminer. It has been reported that the presence of PLR is undetectable
when the PLR is less than a reduction of 0.3mm, which is a 10% PLR in
a 3.0mm pupil diameter [22]. Therefore, it is no wonder that quanti-
tative PLR with a pupillometer can predict outcomes in the post-CA care
earlier than qualitative assessments.
Mortality after CA is primarily accounted for by the withdrawal of
life-sustaining therapy (WLST) [23]. Multi-modal prognostication was
performed in line with the guidelines [10,19]. When poor neurological
prognosis is perceived, most Japanese physicians withhold aggressive
treatments and seldom adopt active WLST. Consequently, mortality did
not concentrate within a week after CA and continued to increase over
3 weeks (Supplemental Fig. 2). Moreover, the results of quantitative
PLR were obtained exclusively for our observational study and were
never used for clinical decision making of WLST. Thus, removing the
risk of creating a self-fulﬁlling prophecy with a lack of blindness to the
results of the quantitative PLR measurements and the WLST, in our
study.
Our study has several limitations. First, the sample size was rela-
tively small. A substantial number of patients were excluded because
informed consent could not be obtained from an accompanied family
member / guardian immediately after ROSC. However, our study was a
multicentre study, which avoids the bias pertaining to previous single-
centre studies. Second, the study does not compare the prognostic ac-
curacy of quantitative PLR measurements with other physiological or
biomarker tests, which are currently used for prognostication in post-
CA care. This study focused speciﬁcally on evaluating the prognostic
accuracy of quantitative PLR in the very early phase with repeated
assessments. A multimodal prognostication approach is recommended
to minimize the rate of false-positive results for predicting poor out-
comes [10,19]. Further large multicentre studies are warranted to
evaluate the utility of quantitative PLR for early prognostication solely,
as well as in a multi-modal prognostic scheme.
Conclusions
Quantitative PLR was consistently greater in 90-day survivors and
patients with favourable neurological outcomes during the ﬁrst 72 h
after ROSC. Quantitative PLR as early as 0 h has a potential role in
prognostication after OHCA; further larger, multicentre studies are
warranted.
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Supplemental Table 1. Usage of specific pharmacologic agents among 90-day survivors and 
non-survivors 
Pharmacologic agents Timing Survivors Non-survivors P value 
Propofol; n (%) 0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
2 (9) 
18 (78) 
21 (91) 
18 (78) 
16 (70) 
15 (65) 
6 (22) 
11 (42) 
8 (38) 
10 (53) 
7 (44) 
8 (57) 
0.19 
0.002 
<0.001 
0.08 
0.11 
0.34 
Midazolam; n (%) 0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
0 
3 (13) 
5 (22) 
3 (13) 
2 (9) 
2 (9) 
6 (22) 
1 (4) 
1 (5) 
0 
0 
1 (8) 
0.02 
0.24 
0.10 
0.10 
0.23 
0.87 
Dexmedetomidine; n (%) 0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
0 
0 
0 
1 (4) 
2 (9) 
0 
0 
1 (4) 
1 (5) 
0 
0 
0 
- 
0.34 
0.29 
0.36 
0.23 
- 
Fentanyl; n (%) 0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
1 (4) 
7 (30) 
5 (22) 
7 (30) 
7 (30) 
4 (17) 
3 (11) 
5 (19) 
7 (33) 
5 (26) 
6 (38) 
4 (29) 
0.38 
0.36 
0.39 
0.77 
0.65 
0.42 
Bupurenprphine; n (%) 0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
0 
7 (30) 
7 (30) 
6 (26) 
6 (26) 
7 (30) 
0 
2 (8) 
2 (10) 
12 (63) 
2 (13) 
2 (14) 
- 
0.04 
0.09 
0.02 
0.30 
0.40 
Norepinephrine; n (%) 
 
0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
1 (4) 
9 (39) 
9 (39) 
9 (39) 
10 (43) 
7 (30) 
9 (33) 
13 (50) 
8 (38) 
11 (58) 
10 (63) 
11 (79) 
0.01 
0.45 
0.94 
0.23 
0.24 
0.005 
Dopamine; n (%) 
 
 
0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
3 (13) 
5 (22) 
5 (22) 
2 (9) 
1 (4) 
3 (13) 
6 (22) 
9 (35) 
5 (24) 
3 (16) 
4 (25) 
4 (27) 
0.40 
0.32 
0.87 
0.48 
0.17 
0.24 
Dobutamine; n (%) 0 h 
6 h 
12 h 
24 h 
48 h 
72 h 
1 (4) 
9 (39) 
10 (43) 
10 (43) 
10 (43) 
10 (43) 
2 (7) 
3 (12) 
7 (30) 
7 (37) 
4 (25) 
7 (36) 
0.65 
0.03 
0.49 
0.66 
0.24 
0.64 
Percentage of the 90-day non-survivors was expressed as the number of patients who were 90-day 
non-survivors and were receiving pharmacologic agents at each time point.
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Supplemental table 2. Prediction of 90-day survival with qualitative PLR assessment 
Time after 
ROSC (h) 
Positive PLR 
in survivors (n) 
Negative PLR 
in non-survivors (n) Sensitivity Specificity NPV (95% CI) 
All patients 
0 12 / 23 23 / 27 0.52 0.85 0.68 (0.49 – 0.83) 
6 13 / 20 19 / 25 0.65 0.76 0.73 (0.52 – 0.88) 
12 13 / 20 14 / 19 0.65 0.74 0.67 (0.43 – 0.85) 
24 13 / 21 11 / 16 0.62 0.69 0.58 (0.33 – 0.80) 
48 15 / 21 10 / 14 0.71 0.71 0.63 (0.35 – 0.85) 
72 17 / 19 12 / 14 0.89 0.86 0.86 (0.57 – 0.98) 
TTM subgroup 
0 11 / 20 12 / 14 0.55 0.86 0.57 (0.34 – 0.78) 
6 12 / 18 9 / 14 0.67 0.64 0.60 (0.32 – 0.84) 
12 12 / 18 9 / 14 0.67 0.64 0.60 (0.32 – 0.84) 
24 11 / 19 8 / 13 0.58 0.62 0.50 (0.25 – 0.75) 
48 13 / 19 8 / 12 0.68 0.67 0.57 (0.29 – 0.82) 
72 16 / 18 9 / 11 0.89 0.82 0.82 (0.48 – 0.98) 
 
CI, confidence interval; PLR, pupillary light reflex; ROSC, return of spontaneous circulation; TTM, target temperature management 
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Supplemental table 3. Prediction of 90-day favourable neurological outcome with qualitative PLR assessment 
Time after 
ROSC (h) 
Positive PLR 
in patients who 
achieved CPC1,2 (n) 
Negative PLR 
in patients who 
achieved CPC3-5 (n) 
Sensitivity Specificity NPV (95% CI) 
All patients 
0 10 / 13 31 / 37 0.77 0.84 0.91 (0.76 – 0.98) 
6 10 / 13 23 / 32 0.77 0.72 0.88 (0.70 – 0.98) 
12 9 / 12 18 / 27 0.75 0.67 0.86 (0.64 – 0.97) 
24  8 / 13 14 / 24 0.62 0.58 0.74 (0.49 – 0.91) 
48 10 / 13 13 / 22 0.77 0.59 0.81 (0.54 – 0.96) 
72 10 / 11 13 / 22 0.91 0.59 0.93 (0.66 – 1.00) 
TTM subgroup 
0  9 / 12 18 / 22 0.75 0.82 0.86 (0.64 – 0.97) 
6  9 / 12 12 / 20 0.75 0.60 0.80 (0.52 – 0.96) 
12  8 / 11 12 / 21 0.73 0.57 0.80 (0.52 – 0.96) 
24  7 / 12 11 / 20 0.58 0.55 0.69 (0.41 – 0.89) 
48  9 / 12 11 / 19 0.75 0.58 0.79 (0.49 – 0.95) 
72 10 / 11 10 / 18 0.91 0.56 0.91 (0.59 – 1.00) 
 
CI, confidence interval; CPC, Cerebral Performance Category; NPV, negative predictive value; PLR, pupillary light reflex; ROSC, return of 
spontaneous circulation; TTM, target temperature management 
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Supplemental figure 1. Patient selection 
 
DNAR, do-not-attempt-resuscitation; ECMO, extracorporeal membrane oxygenation. 
 
 
 
Study patients 
N=50    
Exclusion: N=117 
  ECMO use; n=45 
  Obvious trauma; n=8 
  DNAR order; n=45 
  Pregnant; n=0 
  Impaired brain function; n=9 
  Terminal stage cancer; n=10 
Exclusion: N=187 
  Unable to obtain consent; n=178 
  Referred to other hospital; n=9  
Eligible patients 
N=237   
Adult post-cardiac arrest patients 
N=354    
 6 
 
 
Supplemental Figure 2. Kaplan-Meier survival curve 
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